CTOR · CIK 0001851484 · operating
Based in Cranford, New Jersey, Citius Oncology is a specialty pharmaceutical company focused on developing targeted therapies for oncology indications, particularly rare hematologic malignancies. The company operates as a subsidiary of Leonard-Meron Biosciences, Inc. Its primary development program is LYMPHIR, a therapeutic candidate designated for orphan indication status targeting relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma affecting the skin.
The company's business model centers on the development and commercialization of oncology therapies addressing underserved patient populations. Limited public disclosure is available regarding current revenue streams, employee headcount, or geographic distribution beyond its headquarters location. As a clinical-stage specialty pharmaceutical company with a market capitalization of approximately $0.1 billion, Citius Oncology operates at an early commercial scale typical of companies in focused therapeutic development phases.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.34 | $-0.34 | -9.7% | |
| 2024 | $-0.31 | $-0.31 | -214.8% | |
| 2023 | $0.27 | $0.27 | +125.0% | |
| 2022 | $0.12 | $0.12 | — |